Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

Diabetes Care
Julio RosenstockM B Edwards

Abstract

To determine the safety and efficacy of the long-acting analog insulin glargine compared with NPH insulin in patients with type 2 diabetes who were previously treated with insulin alone. A total of 518 subjects with type 2 diabetes who were receiving NPH insulin with or without regular insulin for postprandial control were randomized to receive insulin glargine (HOE 901) once daily (n = 259) or NPH insulin once or twice daily in = 259) for 28 weeks in an open-label, multicenter trial. Doses were adjusted to obtain target fasting glucose <6.7 mmol/l. At study end point, the median total daily insulin dose in both treatment groups was 0.75 IU/kg. The treatment groups showed similar improvements in HbA1c from baseline to end point on intent-to-treat analysis. The mean change (means +/- SD) in HbA1c from baseline to end point was similar in the insulin glargine group (-0.41 +/- 0.1%) and the NPH group (-0.59 +/- 0.1%) after patients began with an average baseline HbA1c of approximately 8.5%. The treatments were associated with similar reductions in fasting glucose levels. Overall, mild symptomatic hypoglycemia was similar in insulin glargine subjects (61.4%) and NPH insulin subjects (66.%) However, nocturnal hypoglycemia in the ins...Continue Reading

References

Dec 1, 1994·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·J A Galloway, R E Chance
Jan 4, 1997·Lancet·A H Barnett, D R Owens

❮ Previous
Next ❯

Citations

Sep 27, 2002·Diabetes/metabolism Research and Reviews·Philip D Home, Simon G Ashwell
Jul 15, 2009·Diabetologia·U Smith, E A M Gale
Aug 19, 2009·Diabetologia·D Russell-JonesUNKNOWN Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group
Mar 20, 2003·Current Diabetes Reports·M Angelyn Bethel, Mark N Feinglos
Sep 17, 2003·Current Diabetes Reports·Afshin Sasali, Jack L Leahy
Jun 17, 2003·Disease-a-month : DM·Rasa Kazlauskaite, Leon Fogelfeld
Sep 12, 2001·Lancet·D R OwensG B Bolli
Jul 16, 2003·Clinical Therapeutics·Fei WangCunegundo M Vergara
Oct 25, 2002·The New England Journal of Medicine·David M Nathan
Jan 14, 2005·The New England Journal of Medicine·Irl B Hirsch
Jun 28, 2003·Diabetes Technology & Therapeutics·John B Williams
Feb 16, 2010·Diabetes Technology & Therapeutics·Priscilla A HollanderJulio Rosenstock
Jun 28, 2011·Diabetes Technology & Therapeutics·Frank Lavernia
Jun 30, 2011·Diabetes Technology & Therapeutics·Riccardo Perfetti
Jun 28, 2011·Diabetes Technology & Therapeutics·Stuart LittlePhilip Home
Jun 28, 2011·Diabetes Technology & Therapeutics·Maka S HedringtonStephen N Davis
Mar 18, 2011·Metabolic Syndrome and Related Disorders·Katherine EspositoDario Giugliano
Jan 17, 2004·The Nurse Practitioner·Martha M Funnell, Davida F Kruger
Jul 26, 2005·American Journal of Therapeutics·Quanwu Zhang, Laura Menditto
Nov 24, 2006·American Journal of Therapeutics·Athena Philis-TsimikasChris Walker
Apr 9, 2005·Southern Medical Journal·Steven V Edelman, Candis M Morello
Jul 17, 2008·Diabetes, Obesity & Metabolism·C Mathieu, S Robbrecht
Jul 17, 2008·Diabetes, Obesity & Metabolism·S A Schreiber
Jul 17, 2008·Diabetes, Obesity & Metabolism·M Davies, K Khunti
Mar 22, 2008·Diabetes, Obesity & Metabolism·R H A BeckerK Rave
Jan 30, 2009·Diabetes, Obesity & Metabolism·Mariëlle J P van Avendonk, Guy E H M Rutten
Jan 5, 2011·Diabetes, Obesity & Metabolism·B Charbonnel, B Cariou
Feb 1, 2007·International Journal of Clinical Practice·A A TahraniP Moulik
Mar 31, 2007·International Journal of Clinical Practice·J Tibaldi, R E Rakel

❮ Previous
Next ❯

Related Concepts

Related Feeds

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.